good posting as usual jevalent.I had written off any value that...

good posting as usual jevalent.

I had written off any value that AOD9604 may have as has a weight loss drug. (we discussed this previously)Share price down 90%.....obviously the market has also.

Any future worth that the company can extract from that drug in the weight loss area would be a bonus. Very keen to hear what they have to say.

MBP's asx release of 23rd November, 2006 does discuss the results of this research.....re that link provided by jevalent. Probably completely missed by investors because of the weight loss trials.

That info from your post and what the company have to say.......hard not to think,other then MBP may have something special here (I know its hard for some investors to give them a second chance).....but this is what MBP said in November);-

A group of leading academic researchers working independently in the US recently identified the particular module in the body that ACV1 potently blocks, as well as significant additional information about how it may work to relieve pain and apparently repair damaged nerves....

These results, from an independent laboratory, add significantly to Metabolic's understanding of ACV1 and therefore to its potential value.

Its a US$36 million company in a phase 2 trial for a new more effective drug....in a US$5 billion marketplace.
And that comes from an independant well regardes US research facility.